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Abstract
Background: Atherosclerosis lesions contain abundant immunoglobulins complexed with
oxidized LDL (OxLDL) that are endocytosed by macrophages to form foam cells. While recent
evidence supports a role for the macrophage scavenger receptor pathway in 75–90% of OxLDL
uptake, in vitro evidence suggests another potential uptake pathway could involve autoantibody
binding to IgG subclass-specific Fc receptors.
Objective and Methods: To address this mechanism from an in vivo standpoint, the objective of
this study was to utilize flow cytometry to prospectively determine monocyte Fcγ (FcR) I, II, and III
receptor expression levels in patients with acute coronary syndrome (ACS, n = 48), diabetes
mellitus (DM, n = 59), or neither (C, n = 88).
Results: Increased FcR I expression was found in the ACS versus DM groups [geometric mean,
(95% CI) = 2.26 (2.07, 2.47) versus 1.83 (1.69, 1.98) (p < 0.001)] and versus C [1.90 (1.78, 2.03) (p
= 0.005)]. Similar relationships were found with both the FcR II receptor [ACS mean = 4.57 (4.02,
5.19) versus DM 3.61 (3.22, 4.05) (p = 0.021) and versus C 3.86 (3.51, 4.24) (p = 0.09)] and FcR III
receptor [ACS mean = 1.55 (1.44, 1.68) versus DM 1.36 (1.27, 1.46) (p = 0.038) and versus C 1.37
(1.30, 1.45) (p = 0.032)]. There was no difference between DM and C groups in FcR I, II or III
expression.
Conclusions: This in vivo data supports a possible second OxLDL-autoantibody macrophage
uptake mechanism through an Fc receptor-mediated pathway and a potential relationship between
atherosclerotic plaque macrophage FcR levels and ACS.
Introduction
Atherosclerosis is a chronic inflammatory process that
results from hyperlipidemia and complex interactions
involving other genetic and environmental factors.
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through generation of highly immunogenic neodetermi-
nants for the immune system [1]. Natural autoantibody
titer to a number of these epitopes and extent of immune
complex formation may correlate with plaque size and
rate of progression, and plaques have been shown to con-
tain OxLDL/autoantibody immune complexes [2-5]. It is
clear that both innate and adaptive immunity can modu-
late lesion progression and composition, and most stud-
ies to date have indicated a proatherogenic influence of
the immune system on this process [1,4].
Recent evidence supports the macrophage scavenger
receptors SR-A and CD36 as a mechanism responsible for
up to 90% of uptake of OxLDL that leads to foam cell for-
mation with no other scavenger receptors compensating
for their absence in a knockout mouse model [6]. Earlier
evidence involving in vitro incubation of both human
monocyte-derived macrophages and the monocytic cell
line THP-1 with human LDL-rabbit anti-apo B immune
complexes demonstrated a potential role for the FcγRI
receptor in its uptake [7]. A second in vitro study also sug-
gested a potential Fc receptor role through inhibition of
immune complex uptake when Fab or F(ab')2 fragments
were substituted for an intact anti-apo B antibody [8].
Though findings from the latter two studies may have
been partly explained by contributions from the scavenger
pathway, it is reasonable to speculate the Fc receptor path-
way maybe playing a small but important role as well [9-
11].
Immune complexes with modified lipoproteins have
recently emerged as an important coronary artery and
macrovascular disease risk factor in DM [12,13]. Evidence
supports an increased content of macrophages in the
atherosclerotic lesions of persons with DM that is thought
to be due to altered levels of cytokines [12]. Furthermore,
while DM itself does not increase levels of LDL, the small
dense LDL particles found in type 2 DM are more athero-
genic because they are more easily glycated and are
thought to be more susceptible to oxidation [14,15].
In recent work our group has shown FcγRII expression to
be increased in the platelets of patients experiencing an
acute atherothrombotic event, or who are healthy with
two or more atherosclerosis risk factors [16]. Non-acutely
ill diabetes patients have significantly elevated expression
levels and this may play a role in the increased sensitivity
of their platelets to activation by subendothelial collagen
[16-19]. We speculate that Fc expression levels and activity
on macrophages and platelets may represent another link
between the immune system and atherosclerosis progres-
sion and plaque disruption.
In view of the controversy regarding the mechanism of
cholesterol uptake by monocyte-macrophages in athero-
sclerosis and diabetes [20,21] and the previous lack of in
vivo data to help elucidate any role of the Fc receptors in
this process, we have prospectively determined IgG-bind-
ing receptor expression levels for each Fcγ receptor sub-
class on the monocytes of three groups: (1) patients
admitted to the hospital with ACS, (2) well patients with
no history of heart disease but one or more atherosclerosis
risk factors (ARF's) that included DM, and (3) control
patients (with no history of ACS or DM).
Materials and Methods
All 195 patients were randomly chosen for study partici-
pation from a larger group who fit study inclusion criteria
and gave written informed consent. Forty-eight patients in
the study had heart disease (HD) and were within 2 hours
of onset of an ACS (myocardial infarction or unstable
angina), 59 were DM outpatients (both type 1 and type 2
were included) with no known history of HD, and an
additional 88 outpatients without HD or DM were ran-
domly chosen as controls (C). The number and nature of
ARF's was documented for each group (Table 1).
Table 1: Demographic characteristics at enrollment
Characteristic Group 1 (ACS) Group 2 (DM) Group 3 (C) p-value1
Total patients (% with MI Group 1) 48 (52) 59 88
Mean age (years) 56 55 56 0.862
Male (%) 35 (73) 24 (41) 55 (63) 0.002
Positive family history (%)3 6 (13) 21 (36) 21 (24) 0.018
Current cigarette smoker (%) 16 (33) 10 (17) 5 (6) <0.001
Hypertension (%) 29 (60) 29 (49) 20 (23) <0.001
Abnormal lipid profile present (%) 24 (50) 12 (21) 17 (19) <0.001
Diabetes mellitus present (%) 15 (31) 59 (100) 0 (0) <0.001
1. Based on chi-square test.
2. Based on ANOVA F-test
3. One patient in group 2 had missing data with positive family history
(Abbreviations: ACS: acute coronary syndrome; DM: diabetes mellitus; C: control; MI: myocardial infarction)Page 2 of 6
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into 50 µl aliquots to which 5 µl of a saturating concentra-
tion of anti-FcR I (32.2), anti-FcR II (IV.3), anti-FcR III
(3G8), or a negative class-specific control antibody
(MOPC-141, Sigma) was added. Following a 15 minute
incubation, 5 µl of FITC-sheep anti-mouse antibody
(Sigma) was added and a second 15 minute incubation
done. The pellet was washed twice before 5 µl of phyco-
erythrin-conjugated anti-CD14 (Becton Dickinson) was
added and incubated for 15 minutes. The solution was
diluted with 1 ml ammonium chloride lysing solution
and incubated for 10 minutes or until the solution was
clear, and the pellet washed twice before flow cytometry
to determine relative receptor expression levels was car-
ried out according to the manufacturer's specifications
(Becton Dickinson). Monocytes were readily identifiable
from other blood cells by their forward and side scatter
properties along with CD14 expression.
Following establishment of saturating concentrations for
each antibody, mean inter and intra-individual coeffi-
cients of variation for each of the three Fc receptors were
calculated in the antibody labeling assay employing
blood samples from five healthy laboratory volunteers
who met control patient criteria and FcR I values found to
be 3.2 and 9.7%, FcR II 11.7 and 16.1% and FcR III 4.1
and 26.9% respectively.
The ratios of FcR I, FcR II, FcR III and MOPC-141 antibody
expression were calculated for each patient and the loga-
rithm of the ratios were used to analyze the results. An
analysis of variance (ANOVA) was performed to compare
the groups of (1) these 3 ratios with the 3 groups of
patients, (2) the 3 ratios with the total number of major
ARFs, (3) the 3 ratios with each ARF, such as hypertension,
diabetes, and smoking, and (4) the 3 ratios with MI, and
unstable angina in group 1. The overall p-values were
based on the ANOVA F-test. If the overall F-test p-value <
0.05, the LSD method (least significant difference) [22]
was used for multiple comparison. The geometric means
and the associated 95% confidence intervals were calcu-
lated to summarize the data. Patient baseline data
between groups was analyzed using the chi-square test. To
perform statistical analysis, SAS software, version 8.2, was
used (SAS Institute, Inc., Cary, NC).
Results
Significantly increased FcR I expression was found in ACS
patients compared with DM patients [geometric mean FcR
I expression, (95% CI) = 2.26 (2.07, 2.47) versus 1.83
(1.69, 1.98) (p < 0.001)] and compared with C [1.90
(1.78, 2.03) (p = 0.005)] (Table 2, Figure 1). Similar rela-
tionships between the three groups were found to exist
employing antibodies specific to the FcR II receptor: ACS
geometric mean (CI) = 4.57 (4.02, 5.19) versus DM 3.61
(3.22, 4.05) (p = 0.021) and versus C 3.86 (3.51, 4.24) (p
= 0.09) and the FcR III receptor: ACS geometric mean (CI)
= 1.55 (1.44, 1.68) versus DM 1.36 (1.27, 1.46) (p =
0.038) and versus C 1.37 (1.30, 1.45) (p = 0.032). There
was no difference between DM and C groups in FcR I, II or
III expression (p = 0.73, 0.66, and 0.99 respectively).
Table 2: Mean monocyte FcR expression in 195 study patients










Groups <0.0012 0.0242 0.0212
Group 1 (ACS) 48 2.26 (2.07, 2.47) group 1 vs. 2: 0.0013 4.57 (4.02, 5.19) group 1 vs. 2: 
0.0213
1.55 (1.44,1.68) group 1 vs. 2: 
0.0383
Group 2 (DM) 59 1.83 (1.69, 1.98) group 1 vs. 3: 0.0053 3.61 (3.22, 4.05) group 1 vs. 3: 0.093 1.36 (1.27, 1.46) group 1 vs. 3: 
0.0323
Group 3 (C) 88 1.90 (1.78, 2.03) group 2 vs. 3: 0.733 3.86 (3.51, 4.24) group 2 vs. 3: 0.663 1.37 (1.30, 1.45) group 2 vs. 3: 0.99
Adjusted analysis1
Groups 0.0102 0.0612 0.102
Group 1 (ACS) 48 2.33 (2.14, 2.55) group 1 vs. 2: 0.0073 4.57 (4.00, 5.22) group 1 vs. 2: 
0.0503
1.58 (1.45,1.71) group 1 vs. 2: 0.103
Group 2 (DM) 59 1.95 (1.78, 2.13) group 1 vs. 3: 0.093 3.71 (3.24, 4.24) group 1 vs. 3: 0.473 1.41 (1.30, 1.53) group 1 vs. 3: 0.223
Group 3 (C) 88 2.05 (1.87, 2.25) group 2 vs. 3: 0.563 4.11 (3.59, 4.71) group 2 vs. 3: 0.383 1.44 (1.32, 1.56) group 2 vs. 3: 0.433
1. Adjusted by smoking and hypertension status
2. p-value based on F-test
3. p-value based on Tukey-Kramer testPage 3 of 6
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increased expression of any Fc receptor and gender, family
history of premature coronary disease, diabetes, or abnor-
mal lipid profiles. Current cigarette smoking significantly
increased expression of FcR I, 2.24 (2.01, 2.50), compared
to absence of current cigarette smoking, 1.91 (1.82, 2.01)
(p = 0.010) (Table 2 adjusted analysis). FcR II was signifi-
cantly increased among the patients with hypertension,
4.29 (3.88, 4.74) compared to those without hyperten-
sion 3.73 (3.44, 4.05) (p = 0.034). There was a slight
association between age and FcR I, II or III expression (p
= 0.042, 0.050, 0.022 respectively). Expression levels in
younger (age < 45) and older (age > 55) groups were
higher than the middle age group. No difference was
found in FcR expression with respect to ARF number (with
the lone exception of increased FcR III in patients with 2
or more ARFs compared with less than two), or between
the ACS subgroups of acute MI and unstable angina.
When FcR expression is compared between all diabetes
and non-diabetes patients in the 3 groups, there is no dif-
ference in monocyte FcR I, II, or III expression.
Discussion
It can be speculated from this in vivo data that phagocyto-
sis of OxLDL-autoantibody immune complexes by
plaque-associated macrophage through an Fc-mediated
pathway could be a second uptake mechanism in addition
to that involving the scavenger receptors. The potential
clinical implication behind these findings is that while
marrow and blood monocyte scavenger receptors SR-A
and CD36 have not demonstrated inter-individual varia-
bility in their basal expression levels (prior to initial
uptake of OxLDL or differentiation to macrophages)
[23,24], the variable expression of Fcγ receptors found in
this series of patients maybe playing a role in the extent of
OxLDL immune complex uptake by atherosclerosis
plaques. The fact we were able to document relatively
increased surface expression of all three receptor classes in
patients with ACS, along with increased FcR I in those
who smoked and FcR II in those with hypertension, sup-
ports this hypothesis. Any precise pathophysiological
implication behind these findings, though, or any cause
and effect relationship between monocyte Fc expression
and ACS is presently uncertain.
No difference was noted in expression of any Fc receptor
between the diabetes and control groups. Given that the
control group was the largest of the three and that there
was a difference noted in the expression levels of all three
receptors between the two smaller groups, it can be con-
cluded that increasing the sample size of either of the two
groups with similar expression levels could possibly lead
to an increase in the difference between them, but this dif-
ference is still unlikely to be of any significance compared
with that between the ACS group and the other two
groups.
There was an interesting trend in both the unadjusted and
adjusted analyses (Table 2) in which the control groups
had consistently higher monocyte Fc expression levels
compared with the diabetes groups. One potential expla-
nation for this would be the hypothesis that those with
diabetes may have reduced FcR expression levels (with a
possible consequent decreased uptake in oxidized LDL)
compared with non-diabetes subjects in response to rela-
tively higher levels of molecular mediators that support
atherosclerosis progression and a pro-inflammatory, pro-
thrombotic environment. This may reflect a biological
ying-yang type of response that leads to an attempt at
dampening the effects of molecular players capable of
contributing to atherothrombotic events.
An issue pertinent to this study would be the possible
effects of inflammation on monocyte FcR expression lev-
els. In diabetes patients it would be reasonable to specu-
late a significant number of activated cells in the
circulation would be unlikely since in most patients with
atherosclerosis the inflammatory reaction is circum-
scribed to the vessel wall. Overexpression of monocyte Fc
receptors may have been a possibility in ACS however.
Figure 1 shows the ratio of ACS/control mean FcR expres-
sion levels to be very similar between Fc receptor sub-
types. The extent of increased expression associated with
inflammation-associated monocyte activation has been
Monocyte Fcγ receptor subclass expression levels of 48 patients with heart disease (HD) and 59 patients with DM compared wit  88 control patients with neither HD nor DMFigure 1
Monocyte Fcγ receptor subclass expression levels of 48 
patients with heart disease (HD) and 59 patients with DM 
compared with 88 control patients with neither HD nor DM. 
HD patients display significantly increased expression levels 
of all 3 subclasses versus controls. * p = 0.002, 0.037, and 
0.014 for FcR I, FcR II, and FcR III respectively when HD 

















*Page 4 of 6
(page number not for citation purposes)
Immunity & Ageing 2004, 1:4 http://www.immunityageing.com/content/1/1/4shown to be variable between FcR subtypes [25]. In this
respect FcR II and III represent the receptors primarily
involved in the inflammatory response in vivo. Since all
three receptors had uniform increases in expression levels
in ACS compared with controls (with the FcR I ratio being
the highest of the three), it may be reasonable to attribute
a relatively minimal effect of acute inflammation to the
ACS data. Circulating monocyte activation may also have
returned relatively close to baseline as a consequence of
blood being drawn around 2 hours after symptom onset
in most cases. The average circulation time of blood
monocytes in response to an inflammatory stimulus may
fall to as little as 30 minutes [26].
Observational studies of this nature have certain limita-
tions related to their design and patient selection. As an
example, selection bias needs to be considered in any
study involving a population of volunteers associated
with an atherosclerosis prevention trial (Groups 2 and 3).
Even though the ethnic composition of the groups was the
same, the implication of this selection bias is that the
results are not generalizable to the population at large and
this is attested to by the demographic characteristics in
Table 1.
Through bridging innate and adaptive immune processes,
macrophages play an important role in the progression of
atherosclerosis and mediating plaque disruption that is
considered to be the inciting event in the majority of cor-
onary thrombi [27,28]. In this respect there is continual
migration of monocytes between neighboring endothelial
cells as well as two-way migration of monocytes between
blood and OxLDL-containing foam cells when there is
separation of endothelial cells associated with the fatty
streak [29]. This observation and the inherent difficulty in
isolating monocytes from tissues compared with serum
both served as justification for utilizing blood monocyte
Fc expression as a surrogate for plaque macrophage
expression [30].
The overall effect of the humoral immune response on
atherogenesis is likely to be complex. Of note, for exam-
ple, is that the FcγRII receptor has an inhibitory role on B
cells that are rarely seen in plaques, while it mediates
phagocytosis and release of inflammatory mediators from
cells of the myeloid lineage when cross-linked by immune
complexes [31,32]. Thus FcR binding by opsonized
OxLDL could induce either negative or positive regulation
of immune cell responses. Elucidation of the immune
mechanisms involved in atherogenesis will continue to
evolve and lead to new insights into the molecular path-
ways associated with disease progression. Ultimately
these insights will contribute towards the full explanation
behind the clinical diversity of atherosclerosis expression
in patients who appear to have equal risk.
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